NCT05913115View on ClinicalTrials.gov

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

June 19, 2018

Study Completion Date

June 19, 2018

Conditions
Gastric or Gastroesophageal Cancer
Interventions
DRUG

FPA144

FPA144 will be administered intravenously Q2W.

Trial Locations (2)

216-8511

St Marianna University Hospital, Kawasaki-shi

104-0045

National Cancer Center Hospital, Chuo-ku

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY